Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer

✍ Scribed by Içli, Fikri; Karaoguz, Handan; Akbulut, Hakan; Dinçol, Dilek; Demirkazik, Ahmet; Çay, Filiz

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 52 KB
• Volume: 64
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/(sici)1096-9098(199704)64:4<318::aid-jso13>3.0.co;2-z

✦ Synopsis

Background:

Based on the promising results of eap (etoposide, doxorubicin, and cisplatin) combination, a phase ii study of modified eap combination was performed in patients with advanced gastric cancer to evaluate the response, toxicity, and survival.

Method:

Fifty-two consecutive patients with measurable or evaluable advanced gastric cancer, who had no prior therapy except surgery, were treated every 28 days with etoposide 120 mg/m2/day, doxorubicin 25 mg/m2/day, and cisplatin 40 mg/m2/day on days 1 and 8, intravenously. forty-seven patients were evaluable for response and toxicity.

Results:

Overall response rate was 40.5% (95% ci = 37-54.7%), including 12.8% complete response. responses were higher in patients with locally advanced disease (57.89%) as compared to those with distant metastases (28.57%) (p = 0.044). the median overall survivals of the entire group and the responders were 7 months and 11 months, respectively. complete responders had significantly longer response duration and overall survival (31.5 months and 45.5 months, respectively), as compared to partial responders (6 months and 9 months, respectively). six of the responders (31.6%) were alive at 2 years. disease extension and pretreatment performance status had significant effects on survival. grade 3-4 toxicity was observed in 33% of patients. there were no deaths related to toxicity.

Conclusions:

Eap as used in this trial is an effective treatment in advanced gastric cancer. the effect is more pronounced in patients with locally advanced disease.